Artelo Biosciences, Inc. (NASDAQ:ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study—an announcement that underscores a broader story: a multi-platform biotech pipeline built for durability across several high-value therapeutic areas.

Artelo Biosciences is running three distinct clinical-stage programs — in oncology support, neuropathic pain, and CNS disorders — while simultaneously expanding its lead compound into ophthalmology through fully externally funded studies. This isn't a one-trick biotech. It's a platform play in one of medicine's most underserved mechanistic categories.